title: Impact of Parkinson's disease on proprioceptively based on-line movement control.
abstract: Evidence suggests that Parkinson's disease (PD) patients produce large spatial errors when reaching to proprioceptively defined targets. Here, we examined whether these movement inaccuracies result mainly from impaired use of proprioceptive inputs for movement planning mechanisms or from on-line movement guidance. Medicated and non-medicated PD patients and healthy controls performed three-dimensional reaching movements in four sensorimotor conditions that increase proprioceptive processing requirements. We assessed the influence of these sensorimotor conditions on the final accuracy and initial kinematics of the movements. If the patterns of final errors are primarily determined by planning processes before the initiation of the movement, the initial kinematics of reaching movements should show similar trends and predict the pattern of final errors. Medicated and non-medicated PD patients showed a greater mean level of final 3D errors than healthy controls when proprioception was the sole source of information guiding the movement, but this difference reached significance only for medicated PD patients. However, the pattern of initial kinematics and final spatial errors were markedly different both between sensorimotor conditions and between groups. Furthermore, medicated and non-medicated PD patients were less efficient than healthy controls in compensating for their initial spatial errors (hand distance from target location at peak velocity) when aiming at proprioceptively defined compared to visually defined targets. Considered together, the results are consistent with a selective deficit in proprioceptively based movement guidance in PD. Furthermore, dopaminergic medication did not improve proprioceptively guided movements in PD patients, indicating that dopaminergic dysfunction within the basal ganglia is not solely responsible for these deficits.
authors.affiliation: Département de Kinésiologie, Université de Montréal, 2100, boul. Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada, david.mongeon@umontreal.ca.
authors.forename: David
authors.initials: D
authors.lastname: Mongeon
authors.forename: Pierre
authors.initials: P
authors.lastname: Blanchet
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Bergeron
authors.forename: Julie
authors.initials: J
authors.lastname: Messier
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D001696:Biomechanical Phenomena; D015259:Dopamine Agents / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006225:Hand / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009068:Movement / Q000502:physiology*; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D010775:Photic Stimulation; D011434:Proprioception / Q000187:drug effects / Q000502:physiology*; D011597:Psychomotor Performance / Q000187:drug effects; D016059:Range of Motion, Articular / Q000187:drug effects / Q000502:physiology; D012678:Sensation Disorders / Q000188:drug therapy / Q000209:etiology*; D014796:Visual Perception / Q000187:drug effects / Q000502:physiology
chemical_list: D015259:Dopamine Agents